year 16, Issue 5 (September - October 2022)
Iran J Med Microbiol 2022, 16(5): 420-429 |
Back to browse issues page
Somayeh Sadat Moochani1 
, Mohsen Moghoofei2 , Ahmad Tavakoli1 , Alireza Tabibzadeh1 , Saied Ghorbani1 , Hadi Ghaffari3 , Shayan Mostafaei4 , Seyed Hamidreza Monavari 5
, Mohsen Moghoofei2 , Ahmad Tavakoli1 , Alireza Tabibzadeh1 , Saied Ghorbani1 , Hadi Ghaffari3 , Shayan Mostafaei4 , Seyed Hamidreza Monavari 5
1- Department of Medical Virology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
2- Department of Microbiology, Faculty of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran
3- Department of Bacteriology and Virology, Semnan University of Medical Sciences, Semnan, Iran
4- Department of Biostatistics, School of Health, Kermanshah University of Medical Sciences, Kermanshah, Iran
5- Department of Medical Virology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran , hrmonavari@yahoo.com
2- Department of Microbiology, Faculty of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran
3- Department of Bacteriology and Virology, Semnan University of Medical Sciences, Semnan, Iran
4- Department of Biostatistics, School of Health, Kermanshah University of Medical Sciences, Kermanshah, Iran
5- Department of Medical Virology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran , hrmonavari@yahoo.com
Abstract: (1572 Views)
Background and Aim: Currently, HIV, HBV, and HIV/HBV co-infection are important global health issues. It has been estimated that 2.7 million people are co-infected with HIV and HBV worldwide. In recent years, miRNAs have shown promising results as a research area. The current study aimed to investigate the expression level of miRNA-122, miRNA-149, miRNA-199a, and miRNA-let7 in HIV, HBV, HIV/HBV co-infected patients, and healthy controls.
Materials and Methods: In the current study, miRNA expression levels were assessed in PBMC obtained from patients by real-time PCR.
Results: The miRNA-122 was significantly upregulated in HIV/HBV co-infection patients compared with other groups (P<0.001). Also, miRNA-199a and miRNA-let7 were significantly down-regulated in all patient groups compared to the healthy controls (P< 0.001). Correlation analysis demonstrated significant negative correlations between the expression level of miR- 149 and miR-199a with HIV viral load (P<0.001) and HBV viral load, respectively (P<0.01).
Conclusion: This preliminary study could reflect a limited perspective on the field of the miRNAs in HBV and HIV infection. The study suggested further investigation to understand better the role of the miRNA in HIV and HBV infections.
Type of Study: Original Research Article |
Subject:
Medical Virology
Received: 2021/12/20 | Accepted: 2022/05/21 | ePublished: 2022/08/8
Received: 2021/12/20 | Accepted: 2022/05/21 | ePublished: 2022/08/8
References
1. Weidhaas JB, Babar I, Nallur SM, Trang P, Roush S, Boehm M, et al. MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy. Cancer Res. 2007;67(23):11111-6. [DOI:10.1158/0008-5472.CAN-07-2858] [PMID] [PMCID]
2. Maracy MR, Mostafaei S, Moghoofei M, Mansourian M. Impact of HIV risk factors on survival in Iranian HIV-infected patients: A Bayesian approach to retrospective cohort. HIV AIDS Rev Int J HIV-Relat Probl. 2017;16(2):100-6. [DOI:10.5114/hivar.2017.68117]
3. Brenchley JM, Hill BJ, Ambrozak DR, Price DA, Guenaga FJ, Casazza JP, et al. T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: implications for HIV pathogenesis. J Virol. 2004;78(3):1160-8. [DOI:10.1128/JVI.78.3.1160-1168.2004] [PMID] [PMCID]
4. Parvez MK. HBV and HIV co-infection: Impact on liver pathobiology and therapeutic approaches. World J Hepatol. 2015;7(1):121. [DOI:10.4254/wjh.v7.i1.121] [PMID] [PMCID]
5. Singh AE, Wong T. Background document: HIV and hepatitis B co-infection. Department of HIV/AIDS, World Health Organization. 2009.
6. Tajik Z, Bokharaei-Salim F, Ghorbani S, Keyvani H, Esghaei M, Monavari SH, et al. Detection of HBV genome in the plasma and peripheral blood mononuclear cells of Iranian HBsAg negative patients with HIV infection: occult HBV infection. Arch Virol. 2018;163(6):1559-66. [DOI:10.1007/s00705-018-3740-y] [PMID]
7. Organization WH. Global Hepatitis Report 2017. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO.
8. Shata MTM, Abdel-Hameed EA, Rouster SD, Yu L, Liang M, Song E, et al. HBV and HIV/HBV infected patients have distinct immune exhaustion and apoptotic serum biomarker profiles. Pathog Immun. 2019;4(1):39. [DOI:10.20411/pai.v4i1.267] [PMID] [PMCID]
9. Ciardi MR, Iannetta M, Zingaropoli MA, Salpini R, Aragri M, Annecca R, et al., editors. Reactivation of hepatitis B virus with immune-escape mutations after ocrelizumab treatment for multiple sclerosis. Open forum infectious diseases; 2019: Oxford University Press US. [DOI:10.1093/ofid/ofy356] [PMID] [PMCID]
10. Moghoofei M, Mostafaei S, Ashraf-Ganjouei A, Kavosi H, Mahmoudi M. HBV reactivation in rheumatic diseases patients under therapy: A meta-analysis. Microb Pathog. 2018;114:436-43. [DOI:10.1016/j.micpath.2017.12.014] [PMID]
11. Calvaruso V, Ferraro D, Licata A, Bavetta M, Petta S, Bronte F, et al. HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct‐acting antivirals. J Viral Hepat. 2018; 25(1):72-9. [DOI:10.1111/jvh.12754] [PMID]
12. Koziel MJ, Peters MG. Viral hepatitis in HIV infection. New Eng J Med. 2007;356(14):1445-54. [DOI:10.1056/NEJMra065142] [PMID] [PMCID]
13. Singh KP, Crane M, Audsley J, Lewin SR. HIV-Hepatitis B virus co-infection: epidemiology, pathogenesis and treatment. AIDS (London, England). 2017;31(15):2035. [DOI:10.1097/QAD.0000000000001574] [PMID] [PMCID]
14. Iser DM, Lewin SR. The pathogenesis of liver disease in the setting of HIV-hepatitis B virus co-infection. 2011. Iser DM, Lewin SR. The pathogenesis of liver disease in the setting of HIV-hepatitis B virus coinfection. Antivir Ther. 2009;14(2):155-64. [DOI:10.1177/135965350901400207] [PMID]
15. Olawumi H, Olanrewaju D, Shittu A, Durotoye I, Akande A, Nyamngee A. Effect of hepatitis-B virus co-infection on CD4 cell count and liver function of HIV infected patients. Ghana Med. 2014;48(2):96-100. [DOI:10.4314/gmj.v48i2.7] [PMID] [PMCID]
16. Louten J, Beach M, Palermino K, Weeks M, Holenstein G. MicroRNAs expressed during viral infection: biomarker potential and therapeutic considerations. Biomarker insights. 2015;10: BMI-S29512. [DOI:10.4137/BMI.S29512] [PMID] [PMCID]
17. Bhaskaran M, Mohan M. MicroRNAs: history, biogenesis, and their evolving role in animal development and disease. Vet Pathol. 2014; 51 (4):759-74. [DOI:10.1177/0300985813502820] [PMID] [PMCID]
18. MacFarlane L-A, R Murphy P. MicroRNA: biogenesis, function and role in cancer. Curr Genomics. 2010;11(7):537-61. [DOI:10.2174/138920210793175895] [PMID] [PMCID]
19. Ojha CR, Rodriguez M, Dever SM, Mukhopadhyay R, El-Hage N. Mammalian microRNA: an important modulator of host-pathogen interactions in human viral infections. J Biomed Sci. 2016;23(1):1-11. [DOI:10.1186/s12929-016-0292-x] [PMID] [PMCID]
20. Bandiera S, Pfeffer S, Baumert TF, Zeisel MB. miR-122-a key factor and therapeutic target in liver disease. J Hepatol. 2015;62(2):448-57. [DOI:10.1016/j.jhep.2014.10.004] [PMID]
21. Thirion M, Ochiya T. Roles of microRNAs in the hepatitis B virus infection and related diseases. Viruses. 2013;5(11):2690-703. [DOI:10.3390/v5112690] [PMID] [PMCID]
22. Su B, Fu Y, Liu Y, Wu H, Ma P, Zeng W, et al. Potential application of microRNA profiling to the diagnosis and prognosis of HIV-1 infection. Front Microbiol. 2018;9:3185. [DOI:10.3389/fmicb.2018.03185] [PMID] [PMCID]
23. Moghoofei M, Bokharaei-Salim F, Esghaei M, Keyvani H, Honardoost M, Mostafaei S, et al. microRNAs 29, 150, 155, 223 level and their relation to viral and immunological markers in HIV-1 infected naive patients. Future Virol. 2018; 13(09):637-45. [DOI:10.2217/fvl-2018-0055]
24. Neudecker V, Brodsky KS, Kreth S, Ginde AA, Eltzschig HK. Emerging roles for microRNAs in perioperative medicine. Anesthesiology. 2016; 124(2):489-506. [DOI:10.1097/ALN.0000000000000969] [PMID] [PMCID]
25. Swaminathan S, Murray DD, Kelleher AD. mi RNA s and HIV: unforeseen determinants of host‐pathogen interaction. Immunol Rev. 2013;254 (1):265-80. [DOI:10.1111/imr.12077] [PMID]
26. Kosaka N, Iguchi H, Ochiya T. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 2010;101(10):2087-92. [DOI:10.1111/j.1349-7006.2010.01650.x] [PMID]
27. Wang S, Qiu L, Yan X, Jin W, Wang Y, Chen L, et al. Loss of microRNA 122 expression in patients with hepatitis B enhances hepatitis B virus replication through cyclin G1‐modulated P53 activity. Hepatology. 2012;55(3):730-41. [DOI:10.1002/hep.24809] [PMID]
28. Qiu L, Fan H, Jin W, Zhao B, Wang Y, Ju Y, et al. miR-122-induced down-regulation of HO-1 negatively affects miR-122-mediated suppression of HBV. Biochem Biophys Res Commun. 2010;398(4):771-7. [DOI:10.1016/j.bbrc.2010.07.021] [PMID]
29. Tan B, Liu M, Wang L, Wang J, Xiong F, Bao X, et al. Serum microRNAs predict response of patients with chronic hepatitis B to antiviral therapy. Int J Infect Dis. 2021;108:37-44. [DOI:10.1016/j.ijid.2021.05.015] [PMID]
30. Gómez-Gonzalo M, Carretero M, Rullas Jn, Lara-Pezzi E, Aramburu J, Berkhout B, et al. The hepatitis B virus X protein induces HIV-1 replication and transcription in synergy with T-cell activation signals: functional roles of NF-κB/NF-AT and SP1-binding sites in the HIV-1 long terminal repeat promoter. J Biol Chem. 2001;276 (38):35435-43. [DOI:10.1074/jbc.M103020200] [PMID]
31. Soriano V, Puoti M, Bonacini M, Brook G, Cargnel A, Rockstroh J, et al. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. Aids. 2005;19(3):221-40. [DOI:10.1097/01.aids.0000163948.62176.e7] [PMID]
32. Hu J, Xu Y, Hao J, Wang S, Li C, Meng S. MiR-122 in hepatic function and liver diseases. Protein & cell. 2012;3(5):364-71. [DOI:10.1007/s13238-012-2036-3] [PMID] [PMCID]
33. Bandopadhyay M, Sarkar N, Datta S, Das D, Pal A, Panigrahi R, et al. Hepatitis B virus X protein mediated suppression of miRNA-122 expression enhances hepatoblastoma cell proliferation through cyclin G1-p53 axis. Infect Agents Cancer. 2016;11(1):1-12. [DOI:10.1186/s13027-016-0085-6] [PMID] [PMCID]
34. Ebrahimifard M, Zandi M, Moradi A. Evaluation of miR-122 levels in chronic HBV and liver cirrhosis patients. Arch Med Sci. 2016;2(3).
35. Ji F, Yang B, Peng X, Ding H, You H, Tien P. Circulating microRNAs in hepatitis B virus-infected patients. J Viral Hepat. 2011;18(7):e242-e51. [DOI:10.1111/j.1365-2893.2011.01443.x]
36. Song K, Han C, Zhang J, Lu D, Dash S, Feitelson M, et al. Epigenetic regulation of MicroRNA‐122 by peroxisome proliferator activated receptor‐gamma and hepatitis b virus X protein in hepatocellular carcinoma cells. Hepatology. 2013;58(5):1681-92. [DOI:10.1002/hep.26514] [PMID] [PMCID]
37. Yousefpouran S, Mostafaei S, Manesh PV, Iranifar E, Bokharaei-Salim F, Nahand JS, et al. The assessment of selected MiRNAs profile in HIV, HBV, HCV, HIV/HCV, HIV/HBV Co-infection and elite controllers for determination of biomarker. Microb Pathog. 2020;147:104355. [DOI:10.1016/j.micpath.2020.104355] [PMID]
38. Tian P, Yan L. Inhibition of MicroRNA-149-5p induces apoptosis of acute myeloid leukemia cell line THP-1 by targeting fas ligand (FASLG). Med Sci Monit: Int Med J Exp Clin Res. 2016;22:5116. [DOI:10.12659/MSM.899114] [PMID] [PMCID]
39. Hariharan M, Scaria V, Pillai B, Brahmachari SK. Targets for human encoded microRNAs in HIV genes. Biochem Biophys Res Commun. 2005;337 (4):1214-8. [DOI:10.1016/j.bbrc.2005.09.183] [PMID]
40. Wang R, Zhang J, Ma Y, Chen L, Guo S, Zhang X, et al. Association study of miR 149 rs2292832 and miR 608 rs4919510 and the risk of hepatocellular carcinoma in a large scale population. Mol Med Rep. 2014;10(5):2736-44. [DOI:10.3892/mmr.2014.2536] [PMID]
41. Jin L, Hu WL, Jiang CC, Wang JX, Han CC, Chu P, et al. MicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma. Proc Natl Acad Sci U S A. 2011;108(38):15840-5. [DOI:10.1073/pnas.1019312108] [PMID] [PMCID]
42. Squillace N, Bresciani E, Torsello A, Bandera A, Sabbatini F, Giovannetti C, et al. Changes in subcutaneous adipose tissue microRNA expression in HIV-infected patients. J Antimicrob Chemother. 2014;69(11):3067-75. [DOI:10.1093/jac/dku264] [PMID]
43. Qiu D, Chen J, Liu J, Luo Z, Jiang W, Huang J, et al. Expression of microRNA let-7a positively correlates with hepatitis B virus replication in hepatocellular carcinoma tissues. Exp Biol Med. 2017;242(9):939-44. [DOI:10.1177/1535370217697382] [PMID] [PMCID]
44. Kumar MS, Erkeland SJ, Pester RE, Chen CY, Ebert MS, Sharp PA, et al. Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci U S A. 2008;105 (10):3903-8. [DOI:10.1073/pnas.0712321105] [PMID] [PMCID]
45. Lee H, Han S, Kwon CS, Lee D. Biogenesis and regulation of the let-7 miRNAs and their functional implications. Protein & cell. 2016;7(2) :100-13. [DOI:10.1007/s13238-015-0212-y] [PMID] [PMCID]
46. Wang Y, Lu Y, Toh ST, Sung W-K, Tan P, Chow P, et al. Lethal-7 is down-regulated by the hepatitis B virus x protein and targets signal transducer and activator of transcription 3. J Hepatol. 2010; 53(1):57-66. [DOI:10.1016/j.jhep.2009.12.043] [PMID]
47. Swaminathan S, Suzuki K, Seddiki N, Kaplan W, Cowley MJ, Hood CL, et al. Differential regulation of the Let-7 family of microRNAs in CD4+ T cells alters IL-10 expression. J Immunol 2012;188(12): 6238-46. [DOI:10.4049/jimmunol.1101196] [PMID]
48. Zhang G-l, Li Y-x, Zheng S-q, Liu M, Li X, Tang H. Suppression of hepatitis B virus replication by microRNA-199a-3p and microRNA-210. Antiviral Res. 2010;88(2):169-75. [DOI:10.1016/j.antiviral.2010.08.008] [PMID]
49. Santhakumar D, Forster T, Laqtom NN, Fragkoudis R, Dickinson P, Abreu-Goodger C, et al. Combined agonist-antagonist genome-wide functional screening identifies broadly active antiviral microRNAs. Proc Natl Acad Sci U S A. 2010;107(31):13830-5. [DOI:10.1073/pnas.1008861107] [PMID] [PMCID]
50. Hou J, Lin L, Zhou W, Wang Z, Ding G, Dong Q, et al. Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer cell. 2011;19 (2):232-43. [DOI:10.1016/j.ccr.2011.01.001] [PMID]
51. Sekiba K, Otsuka M, Ohno M, Yamagami M, Kishikawa T, Suzuki T, et al. Hepatitis B virus pathogenesis: Fresh insights into hepatitis B virus RNA. World J Gastroenterol. 2018;24(21):2261. [DOI:10.3748/wjg.v24.i21.2261] [PMID] [PMCID]
52. Huang JT, Liu SM, Ma H, Yang Y, Zhang X, Sun H, et al. Systematic review and meta‐analysis: Circulating miRNAs for diagnosis of hepatocellular carcinoma. J Cell Physiol. 2016; 231(2):328-35. [DOI:10.1002/jcp.25135] [PMID]
53. Hydbring P, Badalian-Very G. Clinical applications of microRNAs. F1000Research. 2013;2. [DOI:10.12688/f1000research.2-136.v1] [PMID] [PMCID]
54. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science. 2010;327(5962):198-201. [DOI:10.1126/science.1178178] [PMID] [PMCID]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |